

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Innovax-ILT-IBD concentrate and solvent for suspension for injection for chickens

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of reconstituted vaccine (0.2 ml for subcutaneous use or 0.05 ml for *in ovo* use) contains:

### Active substance:

Cell-associated live recombinant turkey herpesvirus (strain HVT/IBD/ILT), expressing the VP2 protein of infectious bursal disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus:  $10^{3.2} - 10^{4.6}$  PFU<sup>1</sup>.

<sup>1</sup> PFU – plaque forming units.

### Excipients:

Qualitative composition of excipients and other constituents
<b>Concentrate:</b>
Bovine serum
Veggie medium
Dimethyl sulfoxide
<b>Solvent:</b>
Sucrose
Sodium chloride
Disodium hydrogen phosphate dihydrate
Phenolsulfonphthalein (Phenol red)
Potassium dihydrogen phosphate
Water for injections

Concentrate: off-red to red cell concentrate.

Solvent: clear, red solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Chickens and embryonated chicken eggs.

### 3.2 Indications for use for each target species

For active immunisation of one-day-old chicks or 18-19 day-old embryonated chicken eggs:

- to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
- to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (IBD) virus.

Onset of immunity: IBD: 3 weeks of age  
ILT: 4 weeks of age

MD: 5 days of age

Duration of immunity: IBD: 100 weeks  
ILT: 100 weeks  
MD: entire risk period

### **3.3 Contraindications**

None.

### **3.4 Special warnings**

Vaccinate healthy animals only.

Chickens with maternally derived antibodies, when vaccinated with this veterinary medicinal product, may have a delayed onset of immunity against IBD.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety trials have shown that the strain is safe for turkeys. However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The handling of liquid nitrogen should take place in a well-ventilated area. Innovax-ILT-IBD is a virus suspension packed in glass ampoules and stored in liquid nitrogen. Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask or goggles should be worn. In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face. Care should be exercised to prevent contaminating your hands, eyes and clothing with the ampoule content.  
CAUTION: Ampoules have been known to explode on sudden temperature changes. Do not thaw in hot or ice-cold water. For this reason, thaw the ampoules in clean water at 25 °C – 27 °C.

Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet.

### **3.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during lay.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Safety and efficacy data are available which demonstrate that the vaccine Innovax-ILT-IBD can be mixed in the same solvent and administered by either *in ovo* or subcutaneous route with Nobilis Rismavac.

Safety and efficacy data are available which demonstrate that this vaccine can be administered to one-day-old chicks on the same day but not mixed with Nobilis ND Clone 30 or Nobilis ND C2 or Nobilis IB Ma5 or Nobilis IB 4-91. For such associated uses, an onset of immunity of 3 weeks has been demonstrated for ND and IB.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### 3.9 Administration routes and dosage

#### Posology:

Subcutaneous use: one single injection of 0.2 ml per chick.

*In ovo*: one single injection of 0.05 ml per egg.

#### Preparation of the vaccine:

The usual aseptic precautions should be applied to all preparation and administration procedures. The handling of liquid nitrogen should take place in a well-ventilated area.

1. Use solvent for cell associated poultry vaccines for reconstitution. Reconstitute the vaccine according to the tables below:

For subcutaneous use reconstitute the vaccine according to the table below:

Solvent bag	Number of vaccine ampoules for subcutaneous use
Bag of 400 ml solvent	1 ampoule containing 2000 doses
Bag of 800 ml solvent	2 ampoules containing 2000 doses
Bag of 800 ml solvent	1 ampoule containing 4000 doses
Bag of 1200 ml solvent	3 ampoules containing 2000 doses
Bag of 1600 ml solvent	4 ampoules containing 2000 doses
Bag of 1600 ml solvent	2 ampoules containing 4000 doses

For *in ovo* use reconstitute the vaccine according to the table below:

Solvent bag	Number of vaccine ampoules for <i>in ovo</i> use
Bag of 400 ml solvent	4 ampoules containing 2000 doses
Bag of 400 ml solvent	2 ampoules containing 4000 doses
Bag of 800 ml solvent	8 ampoules containing 2000 doses
Bag of 800 ml solvent	4 ampoules containing 4000 doses
Bag of 1200 ml solvent	12 ampoules containing 2000 doses
Bag of 1200 ml solvent	6 ampoules containing 4000 doses
Bag of 1600 ml solvent	16 ampoules containing 2000 doses
Bag of 1600 ml solvent	8 ampoules containing 4000 doses

The solvent must be clear, red coloured, without sediment and at room temperature (15 °C – 25 °C) at the time of mixing.

2. Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be

- calculated first. There is no information available on the number of doses on the ampoules once they are removed from the cane, so special care has to be taken to ensure that the mix-ups of ampoules with different number of doses is avoided and the correct solvent is used.
3. Before withdrawing the ampoules from the liquid nitrogen container, protect hands with gloves, wear long sleeves and use a facemask or goggles. When removing an ampoule from the cane, hold in the palm of a gloved hand away from the body and the face.
  4. When withdrawing a cane of ampoules from the canister in the liquid nitrogen container, expose only the ampoule(s) to be used immediately. It is recommended to handle a maximum of 5 ampoules (from one can only) at a time. After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
  5. The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25 °C – 27 °C. Gently swirl the ampoule(s) to disperse the contents. It is important that the ampoule content, after being thawed, is mixed immediately into the solvent to protect the cells. Dry the ampoule, then break the ampoule at its neck and immediately proceed as described below.
  6. Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18-gauge needle.
  7. Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent. Gently swirl and invert the bag to mix the vaccine. Withdraw a portion of the solvent into the syringe to rinse the ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag.
  8. Repeat steps 6 and 7 for additional ampoules, if required.
  9. Remove the syringe and invert the bag (6–8 times) to mix the vaccine.
  10. The vaccine is now ready for use.  
After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.

When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2000 doses of both products or 800 ml of solvent for each 4000 doses of both products).

#### Administration:

The vaccine is administered by subcutaneous injection in the neck or by *in ovo* injection. The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g., during long vaccination sessions).

#### Control of correct storage:

To allow a check on correct storage and transport the ampoules are placed upside down in the liquid nitrogen containers. If frozen content is situated in the tip of the ampoule this indicates that the content has been thawed and must not be used.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No symptoms were observed after the administration of a 10-fold dose of vaccine.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI01AD18.**

The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the VP2 protein of infectious bursal disease virus and the gD and gI glycoproteins of infectious laryngotracheitis virus. The vaccine induces active immunity against infectious bursal disease (Gumboro disease), infectious laryngotracheitis and Marek's disease in chickens.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product or Nobilis Rismavac.

### **5.2 Shelf life**

Shelf life of the concentrate as packaged for sale: 3 years.

Shelf life of the solvent (multilayer plastic bags) as packaged for sale: 3 years.

Shelf life after reconstitution according to directions: 2 hours.

### **5.3 Special precautions for storage**

#### Concentrate:

Store and transport frozen in liquid nitrogen (below -140 °C).

#### Solvent:

Store below 30 °C.

#### Container:

Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.

### **5.4 Nature and composition of immediate packaging**

#### Concentrate:

- Type I glass ampoule of 2 ml containing 2000 or 4000 doses. Ampoules are stored on a cane and attached to the cane is a coloured clip displaying the dose (2000 doses: salmon-pink coloured clip, and 4000 doses: yellow coloured clip).

#### Solvent:

- One 400 ml multilayer plastic bag.
- One 800 ml multilayer plastic bag.
- One 1200 ml multilayer plastic bag.
- One 1600 ml multilayer plastic bag.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/23/292/001-002

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 14 April 2023.

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**AMPOULE 2000/4000 doses**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Innovax-ILT-IBD

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

HVT/IBD/ILT

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**SOLVENT BAG 400/800/1200/1600 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for cell associated poultry vaccines

**2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

400 ml  
800 ml  
1200 ml  
1600 ml

**3. ROUTE(S) OF ADMINISTRATION**

Read package leaflet before use.

**4. STORAGE CONDITIONS**

Store below 30 °C.

**5. BATCH NUMBER**

Lot {number}

**6. EXPIRY DATE**

EXP {MM/YYYY}

**7. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Innovax-ILT-IBD concentrate and solvent for suspension for injection for chickens

### 2. Composition

Each dose of reconstituted vaccine (0.2 ml for subcutaneous use or 0.05 ml for *in ovo* use) contains:

Cell-associated live recombinant turkey herpesvirus (strain HVT/IBD/ILT), expressing the VP2 protein of infectious bursal disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus:  $10^{3.2} - 10^{4.6}$  PFU<sup>1</sup>.

<sup>1</sup> PFU – plaque forming units.

Concentrate: off-red to red cell concentrate.

Solvent: clear, red solution.

### 3. Target species

Chickens and embryonated chicken eggs.

### 4. Indications for use

For active immunisation of one-day-old chicks or 18-19 day-old embryonated chicken eggs:

- to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
- to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (IBD) virus.

Onset of immunity:      IBD: 3 weeks of age  
                                  ILT: 4 weeks of age  
                                  MD: 5 days of age

Duration of immunity:  IBD: 100 weeks  
                                  ILT: 100 weeks  
                                  MD: entire risk period

### 5. Contraindications

None.

### 6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Chickens with maternally derived antibodies, when vaccinated with this veterinary medicinal product, may have a delayed onset of immunity against IBD.

Special precautions for safe use in the target species:

As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety trials have shown that the strain is safe for turkeys. However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The handling of liquid nitrogen should take place in a well-ventilated area.

Innovax-ILT-IBD is a virus suspension packed in glass ampoules and stored in liquid nitrogen. Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask or goggles should be worn. In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face. Care should be exercised to prevent contaminating your hands, eyes and clothing with the ampoule content. CAUTION: Ampoules have been known to explode on sudden temperature changes. Do not thaw in hot or ice-cold water. For this reason, thaw the ampoules in clean water at 25 °C – 27 °C.

Special precautions for the protection of the environment:

Not applicable.

Laying birds:

The safety of the veterinary medicinal product has not been established during lay.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that the vaccine Innovax-ILT-IBD can be mixed in the same solvent and administered by either *in ovo* or subcutaneous route with Nobilis Rismavac.

Safety and efficacy data are available which demonstrate that this vaccine can be administered to one-day-old chicks on the same day but not mixed with Nobilis ND Clone 30 or Nobilis ND C2 or Nobilis IB Ma5 or Nobilis IB 4-91. For such associated uses, an onset of immunity of 3 weeks has been demonstrated for ND and IB.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No symptoms were observed after the administration of a 10-fold dose of vaccine.

Special restrictions for use and special conditions for use:

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

Major incompatibilities:

Do not mix with any other veterinary medicinal product except the solvent supplied for use with the veterinary medicinal product or Nobilis Rismavac.

**7. Adverse events**

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## 8. Dosage for each species, routes and method of administration

After dilution, administer one dose of 0.2 ml vaccine per chicken by subcutaneous injection in the neck or one dose of 0.05 ml per egg by *in ovo* injection.

## 9. Advice on correct administration

The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g., during long vaccination sessions).

### Preparation of the vaccine:

The usual aseptic precautions should be applied to all preparation and administration procedures. The handling of liquid nitrogen should take place in a well-ventilated area.

1. Use solvent for cell associated poultry vaccines for reconstitution. Reconstitute the vaccine according to the tables below:

For subcutaneous use reconstitute the vaccine according to the table below:

Solvent bag	Number of vaccine ampoules for subcutaneous use
Bag of 400 ml solvent	1 ampoule containing 2000 doses
Bag of 800 ml solvent	2 ampoules containing 2000 doses
Bag of 800 ml solvent	1 ampoule containing 4000 doses
Bag of 1200 ml solvent	3 ampoules containing 2000 doses
Bag of 1600 ml solvent	4 ampoules containing 2000 doses
Bag of 1600 ml solvent	2 ampoules containing 4000 doses

For *in ovo* use reconstitute the vaccine according to the table below:

Solvent bag	Number of vaccine ampoules for <i>in ovo</i> use
Bag of 400 ml solvent	4 ampoules containing 2000 doses
Bag of 400 ml solvent	2 ampoules containing 4000 doses
Bag of 800 ml solvent	8 ampoules containing 2000 doses
Bag of 800 ml solvent	4 ampoules containing 4000 doses
Bag of 1200 ml solvent	12 ampoules containing 2000 doses
Bag of 1200 ml solvent	6 ampoules containing 4000 doses
Bag of 1600 ml solvent	16 ampoules containing 2000 doses
Bag of 1600 ml solvent	8 ampoules containing 4000 doses

The solvent must be clear, red coloured, without sediment and at room temperature (15 °C – 25 °C) at the time of mixing.

2. Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be calculated first. There is no information available on the number of doses on the ampoules once they are removed from the can, so special care has to be taken to ensure that the mix-ups of ampoules with different number of doses is avoided and the correct solvent is used.



3. Before withdrawing the ampoules from the liquid nitrogen container, protect hands with gloves, wear long sleeves and use a facemask or goggles. When removing an ampoule from the cane, hold in the palm of a gloved hand away from the body and the face.
4. When withdrawing a cane of ampoules from the canister in the liquid nitrogen container, expose only the ampoule(s) to be used immediately. It is recommended to handle a maximum of 5 ampoules (from one can only) at a time. After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
5. The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25 °C – 27 °C. Gently swirl the ampoule(s) to disperse the contents. It is important that the ampoule content, after being thawed, is mixed immediately into the solvent to protect the cells. Dry the ampoule, then break the ampoule at its neck and immediately proceed as described below.
6. Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18-gauge needle.
7. Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent. Gently swirl and invert the bag to mix the vaccine. Withdraw a portion of the solvent into the syringe to rinse the ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag
8. Repeat steps 6 and 7 for additional ampoules, if required.
9. Remove the syringe and invert the bag (6–8 times) to mix the vaccine.
10. The vaccine is now ready for use.  
After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.

When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2000 doses of both products or 800 ml of solvent for each 4000 doses of both products).

Control of correct storage:

To allow a check on correct storage and transport the ampoules are placed upside down in the liquid nitrogen containers. If frozen content is situated in the tip of the ampoule this indicates that the content has been thawed and must not be used.

**10. Withdrawal periods**

Zero days.

**11. Special storage precautions**

Keep out of the sight and reach of children.

Concentrate: Store and transport frozen in liquid nitrogen (below –140 °C).

Solvent: Store below 30 °C.

Container: Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.

Do not use this veterinary medicinal product after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: 2 hours.

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

EU/2/23/292/001-002

#### Pack sizes:

1 ampoule containing 2000 or 4000 doses. Ampoules are stored on a cane and attached to the cane is a coloured clip displaying the dose (2000 doses: salmon-pink coloured clip, and 4000 doses: yellow coloured clip).

Bag of 400 ml solvent, bag of 800 ml solvent, bag of 1200 ml solvent or bag of 1600 ml solvent.

Not all pack sizes may be marketed.

### **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

### **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

Intervet International B.V., Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands

#### **België/Belgique/Belgien**

Tél/Tel: + 32 (0)2 370 94 01

#### **Lietuva**

Tel: + 37052196111

#### **Република България**

Тел: + 359 28193749

#### **Luxembourg/Luxemburg**

Tél/Tel: + 32 (0)2 370 94 01

#### **Česká republika**

Tel: +420 233 010 242

#### **Magyarország**

Tel.: + 36 1 439 4597

#### **Danmark**

Tlf: + 45 44 82 42 00

#### **Malta**

Tel: + 39 02 516861

#### **Deutschland**

Tel: + 49 (0)8945614100

#### **Nederland**

Tel: + 32 (0)2 370 94 01

**Eesti**

Tel: + 37052196111

**Ελλάδα**

Τηλ: + 30 210 989 7452

**España**

Tel: + 34 923 19 03 45

**France**

Tél: + 33 (0)241228383

**Hrvatska**

Tel: + 385 1 6611339

**Ireland**

Tel: + 353 (0) 1 2970220

**Ísland**

Sími: + 354 535 7000

**Italia**

Tel: + 39 02 516861

**Κύπρος**

Τηλ: +30 210 989 7452

**Latvija**

Tel: + 37052196111

**Norge**

Tlf: + 47 55 54 37 35

**Österreich**

Tel: + 43 (1) 256 87 87

**Polska**

Tel.: + 48 22 18 32 200

**Portugal**

Tel: + 351 214 465 700

**România**

Tel: + 40 21 311 83 11

**Slovenija**

Tel: + 385 1 6611339

**Slovenská republika**

Tel: +420 233 010 242

**Suomi/Finland**

Puh/Tel: + 358 10 2310 750

**Sverige**

Tel: + 46 (0)8 522 216 60

**United Kingdom (Northern Ireland)**

Tel: + 353 (0) 1 2970220

**17. Other information**

The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the VP2 protein of infectious bursal disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus. The vaccine induces active immunity against infectious bursal disease (Gumboro disease), infectious laryngotracheitis and Marek's disease in chickens.